The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...

Image Credit: KK Stock/Shutterstock.com In a recent study published in the eClinicalMedicine, a group of researchers evaluated the association between Glucagon-like peptide-1 receptor agonists ...

Glucagon-Like Peptide-2 (GLP-2 ... factors can influence the expression of GLP-2 receptors, suggesting that metabolic states can modulate GLP-2 signaling in the central nervous system[5].

With glucagon-like peptide 1 (GLP-1) agonists now close to ... Studies suggest muscle loss with GLP-1 receptor agonists (GLP-1 RAs) ranges from fat-free mass (FFM) decreases of 25%-39% of the ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...